SG11201811074RA - Nant cancer vaccine - Google Patents

Nant cancer vaccine

Info

Publication number
SG11201811074RA
SG11201811074RA SG11201811074RA SG11201811074RA SG11201811074RA SG 11201811074R A SG11201811074R A SG 11201811074RA SG 11201811074R A SG11201811074R A SG 11201811074RA SG 11201811074R A SG11201811074R A SG 11201811074RA SG 11201811074R A SG11201811074R A SG 11201811074RA
Authority
SG
Singapore
Prior art keywords
international
california
jefferson
boulevard
culver city
Prior art date
Application number
SG11201811074RA
Inventor
Patrick Soon-Shiong
Kayvan Niazi
Shahrooz Rabizadeh
Original Assignee
Nant Holdings Ip Llc
Nantcell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nant Holdings Ip Llc, Nantcell Inc filed Critical Nant Holdings Ip Llc
Publication of SG11201811074RA publication Critical patent/SG11201811074RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464482—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111011101 HIM 01101010111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number 0 (43) International Publication Date .....0\"\" WO 2018/005973 Al 04 January 2018 (04.01.2018) W I PO I PCT — (51) (21) (22) (25) Filing Language: (26) (30) International Patent Classification: NANTCELL, INC. [US/US]; 9920 Jefferson Boulevard, A61K 38/38 (2006.01) A61K 31/69 (2006.01) Culver City, California 90232 (US). A61K 39/395 (2006.01) A61K 39/00 (2006.01) (72) Inventors: SOON-SHIONG, Patrick; 9920 Jefferson A61K 31/4184 (2006.01) Boulevard, Culver City, California 90232 (US). NIAZI, International Application Number: Kayvan; 9920 Jefferson Boulevard, Culver City, Califor- PCT/US2017/040297 nia 90232 (US). RABIZADEH, Shahrooz; 9920 Jefferson Boulevard, Culver City, California 90232 (US). International Filing Date: 30 June 2017 (30.06.2017) (74) Agent: FESSENMAIER, Martin; Umberg Zipser LLP, 1920 Main Street, Suite 750, Irvine, California 92614 (US). English Publication Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/357,324 30 June 2016 (30.06.2016) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/371,665 05 August 2016 (05.08.2016) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/393,528 12 September 2016 (12.09.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/404,753 05 October 2016 (05.10.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/463,037 24 February 2017 (24.02.2017) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/473,207 17 March 2017 (17.03.2017) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/474,034 20 March 2017 (20.03.2017) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicants: NANT HOLDINGS IP, LLC [US/US]; 9920 Jefferson Boulevard, Culver City, California 90232 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) = — Title: NANT : from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting. (54) CANCER VACCINE r— ed g OPS Mu /AO.. NW: a az • o• `,ara _ that drive a = 3 , '• = = = - - = = = i r „ Killer Ille I IOW fliK) CO a , C¢33 4' .06Ine T ,.0 4? s s i ua Cold Oss.th D, , ,!; ,E; t,, ,,, ,,..ptamcv , .. = = - TI M IN 01 ir) 0 0 --..... 00 Il (57) C:::: ) tumor ei C Figure 2 Cancer is treated using coordinated treatment regimens that uses various compounds and compositions [Continued on next page] WO 2018/005973 Al MIDEDIMOMOIDEIREEMOOVIIMIMOillini0VOIS GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with amended claims (Art. 19(1))
SG11201811074RA 2016-06-30 2017-06-30 Nant cancer vaccine SG11201811074RA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662357324P 2016-06-30 2016-06-30
US201662371665P 2016-08-05 2016-08-05
US201662393528P 2016-09-12 2016-09-12
US201662404753P 2016-10-05 2016-10-05
US201762463037P 2017-02-24 2017-02-24
US201762473207P 2017-03-17 2017-03-17
US201762474034P 2017-03-20 2017-03-20
PCT/US2017/040297 WO2018005973A1 (en) 2016-06-30 2017-06-30 Nant cancer vaccine

Publications (1)

Publication Number Publication Date
SG11201811074RA true SG11201811074RA (en) 2019-01-30

Family

ID=60787592

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811074RA SG11201811074RA (en) 2016-06-30 2017-06-30 Nant cancer vaccine

Country Status (12)

Country Link
US (3) US11207392B2 (en)
EP (2) EP3478312A4 (en)
JP (2) JP2019524692A (en)
KR (2) KR20190031492A (en)
CN (1) CN109789190A (en)
AU (2) AU2017290803A1 (en)
CA (1) CA3027911A1 (en)
IL (1) IL264023A (en)
MX (1) MX2018015796A (en)
SG (1) SG11201811074RA (en)
TW (1) TW201803598A (en)
WO (1) WO2018005973A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018003631A2 (en) 2015-08-25 2018-09-25 Nantomics Llc systems and methods for high precision variant search
KR102194188B1 (en) 2015-11-18 2020-12-24 머크 샤프 앤드 돔 코포레이션 PD1 and/or LAG3 binder
TW201803598A (en) 2016-06-30 2018-02-01 南特細胞公司 NANT cancer vaccine
CA3042238C (en) * 2016-10-28 2021-08-10 Nant Holdings Ip, Llc Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death
JP7300394B2 (en) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death
US20200248267A1 (en) * 2017-05-03 2020-08-06 Nantomics, Llc TUMOR VS. MATCHED NORMAL cfRNA
EP3622071A4 (en) * 2017-05-10 2020-05-20 Nantomics, LLC Circulating rna for detection, prediction, and monitoring of cancer
CA3128202A1 (en) * 2017-05-11 2018-11-15 Nantkwest, Inc. Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment
AU2018283402A1 (en) * 2017-06-16 2020-01-30 Nantbio, Inc. Bacterial vaccine
US20200352972A1 (en) * 2017-09-06 2020-11-12 Nantcell, Inc. Aldoxorubicin combination treatments and methods
US10752682B2 (en) 2017-11-01 2020-08-25 Nantbio, Inc. Anti-IL8 antibodies
US11823773B2 (en) * 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies
TW202345890A (en) * 2018-04-23 2023-12-01 美商南特細胞公司 Neoepitope vaccine and immune stimulant combinations and methods
US11564980B2 (en) 2018-04-23 2023-01-31 Nantcell, Inc. Tumor treatment method with an individualized peptide vaccine
WO2020018425A1 (en) * 2018-07-16 2020-01-23 Nantcell, Inc. Antibody-dependent cell-mediated toxicity mediated by alt-803 and neo-201
WO2020061419A1 (en) * 2018-09-20 2020-03-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Targeting moiety-drug grafted immune cell compositions and methods of use
EP3938495A4 (en) 2019-03-15 2023-04-26 Nantcell, Inc. Recombinant eril-15 nk cells
WO2021071468A1 (en) * 2019-10-07 2021-04-15 Nantcell, Inc. Neoepitope vaccine and immune stimulant combinations and methods
WO2021096970A1 (en) * 2019-11-12 2021-05-20 Immunitybio, Inc. Natural killer cell therapies
WO2021108641A1 (en) 2019-11-27 2021-06-03 Immunitybio, Inc. Methods of treating cancer
US20240000840A1 (en) * 2020-12-17 2024-01-04 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd20 targeted antibody
US20230285528A1 (en) * 2022-03-08 2023-09-14 Immunitybio, Inc. Intratumorally injected yeast vaccine

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3248600T1 (en) 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN101291658B (en) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 Compositions and methods for preparation of poorly water soluble drugs with increased stability
HUE048521T2 (en) 2005-08-31 2020-08-28 Abraxis Bioscience Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
JP5548874B2 (en) * 2010-03-31 2014-07-16 富山県 Cancer immunosuppression releasing agent and cancer immunotherapy composition
CA2796272C (en) 2010-04-29 2019-10-01 The Regents Of The University Of California Pathway recognition algorithm using data integration on genomic models (paradigm)
US10192641B2 (en) 2010-04-29 2019-01-29 The Regents Of The University Of California Method of generating a dynamic pathway map
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
CA2797645C (en) 2010-05-25 2020-09-22 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
US11017897B2 (en) 2011-03-22 2021-05-25 Nant Holdings Ip, Llc Healthcare management objects
JP6448533B2 (en) 2012-05-15 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Cancer immunotherapy by disrupting PD-1 / PD-L1 signaling
WO2013192339A1 (en) * 2012-06-19 2013-12-27 The Regents Of The University Of California Biomarkers for the immunoediting-escape phase
WO2014008434A2 (en) 2012-07-06 2014-01-09 Nant Holdings Ip, Llc Healthcare analysis stream management
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2907039B1 (en) 2012-10-09 2018-12-19 Five3 Genomics, LLC Systems and methods for learning and identification of regulatory interactions in biological pathways
JP6361039B2 (en) * 2013-04-03 2018-07-25 アイビーシー ファーマスーティカルズ，インコーポレイテッド Combination therapy to induce immune response to disease
JP6216044B2 (en) 2013-05-28 2017-10-18 ファイヴ３ ゲノミクス，エルエルシー PARADIGM drug reaction network
CN110444289A (en) 2013-06-28 2019-11-12 南托米克斯有限责任公司 For diagnosing the path analysis of the identification of detection
US10114925B2 (en) 2013-07-26 2018-10-30 Nant Holdings Ip, Llc Discovery routing systems and engines
WO2015095811A2 (en) * 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2015097536A2 (en) * 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
CN104861067A (en) * 2014-01-10 2015-08-26 博笛生物科技有限公司 Compound for immunotherapy, and composition
JOP20200094A1 (en) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JP6195682B2 (en) 2014-05-30 2017-09-13 ナントミクス，エルエルシー Systems and methods for comprehensive analysis of molecular images across multiple tumors and germline exomes
CN112494646A (en) * 2014-06-30 2021-03-16 阿尔托生物科学有限公司 IL-15-based molecules, methods and uses thereof
EP3166976B1 (en) * 2014-07-09 2022-02-23 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
US9446148B2 (en) * 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
HUE047393T2 (en) * 2014-10-06 2020-04-28 Mayo Found Medical Education & Res Carrier-antibody compositions and methods of making and using the same
AU2015333728B2 (en) 2014-10-14 2020-07-30 Riptide Bioscience, Inc. Peptide-based methods for treating pancreatic cancer
TWI716362B (en) 2014-10-14 2021-01-21 瑞士商諾華公司 Antibody molecules to pd-l1 and uses thereof
US10813952B2 (en) * 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
WO2016118527A1 (en) 2015-01-20 2016-07-28 Nantomics, Llc Systems and methods for response prediction to chemotherapy in high grade bladder cancer
EP3280738A4 (en) 2015-04-08 2019-01-02 Nantomics, LLC Cancer neoepitopes
CN108513593A (en) 2015-04-23 2018-09-07 南托米克斯有限责任公司 The new epitope of cancer
CN108025051B (en) * 2015-07-29 2021-12-24 诺华股份有限公司 Combination therapy comprising anti-PD-1 antibody molecules
BR112018003631A2 (en) 2015-08-25 2018-09-25 Nantomics Llc systems and methods for high precision variant search
CN108601820A (en) 2015-10-12 2018-09-28 南托米克斯有限责任公司 Composition and method for the new epitope of viral cancer
TWI733719B (en) 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 Improved compositions and methods for viral delivery of neoepitopes and uses thereof
CN109069598A (en) 2016-02-11 2018-12-21 河谷控股Ip有限责任公司 Bi-target adenovirus subcutaneous delivery
EP3430148A4 (en) 2016-03-18 2020-01-01 Nantcell, Inc. Multimodal vector for dendritic cell infection
MX2018014602A (en) 2016-05-27 2019-06-10 Etubics Corp Neoepitope vaccine compositions and methods of use thereof.
TW201805013A (en) * 2016-06-03 2018-02-16 美商依圖比克斯公司 Compositions and methods for tumor vaccination and immunotherapy involving HER2/NEU
TW201803598A (en) 2016-06-30 2018-02-01 南特細胞公司 NANT cancer vaccine

Also Published As

Publication number Publication date
JP2021155442A (en) 2021-10-07
EP3478312A1 (en) 2019-05-08
US11207392B2 (en) 2021-12-28
US11071774B2 (en) 2021-07-27
CN109789190A (en) 2019-05-21
WO2018005973A1 (en) 2018-01-04
TW201803598A (en) 2018-02-01
IL264023A (en) 2019-01-31
US20210353730A1 (en) 2021-11-18
CA3027911A1 (en) 2018-01-04
EP3478312A4 (en) 2020-07-29
JP2019524692A (en) 2019-09-05
US20190381156A1 (en) 2019-12-19
MX2018015796A (en) 2019-05-16
AU2020244589A1 (en) 2020-11-05
KR20210010678A (en) 2021-01-27
US11439697B2 (en) 2022-09-13
US20200171137A1 (en) 2020-06-04
AU2017290803A1 (en) 2019-01-24
EP4101447A1 (en) 2022-12-14
KR20190031492A (en) 2019-03-26

Similar Documents

Publication Publication Date Title
SG11201811074RA (en) Nant cancer vaccine
SG11201807770RA (en) Sequence arrangements and sequences for neoepitope presentation
SG11201808990QA (en) Compositions for topical application of compounds
SG11201907744QA (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201907023UA (en) Method of reducing neutropenia
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201808125RA (en) Methods for solid tumor treatment
SG11201903483VA (en) Compositions and methods for treating ezh2-mediated cancer
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201808108XA (en) Synthesis of indazoles
SG11201805001UA (en) Method of treating influenza a
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201810333UA (en) Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201901925RA (en) Methods of treating acute kidney injury